Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30

$3.11−0.11 (-3.42%)

Close on Nov 13, 2026Market cap $538.47MP/E –Yield –

Entera Bio total assets

Total assets on the balance sheet at the end of each period.

Entera Bio's total assets was $277.04M at Sep 30, 2026. For fiscal 2025 it was $15.99M, up 70.3% from the year before. The highest annual figure on record is $25.99M in fiscal 2021.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$15.99M	+70.3%
FY2024	Dec 31, 2024	$9.39M	-20.2%
FY2023	Dec 31, 2023	$11.77M	-10.4%
FY2022	Dec 31, 2022	$13.13M	-49.5%
FY2021	Dec 31, 2021	$25.99M	+167.3%
FY2020	Dec 31, 2020	$9.72M	-41.8%
FY2019	Dec 31, 2019	$16.70M	+25.2%
FY2018	Dec 31, 2018	$13.34M	+0.5%
FY2017	Dec 31, 2017	$13.28M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$277.04M	+1491.5%
Q2 FY2026	Jun 30, 2026	$19.48M	-1.0%
Q1 FY2026	Mar 31, 2026	$13.13M	-39.2%
Q4 FY2025	Dec 31, 2025	$15.99M	+70.3%
Q3 FY2025	Sep 30, 2025	$17.41M	+124.9%
Q2 FY2025	Jun 30, 2025	$19.67M	+96.0%
Q1 FY2025	Mar 31, 2025	$21.60M	+111.0%
Q4 FY2024	Dec 31, 2024	$9.39M	-20.2%
Q3 FY2024	Sep 30, 2024	$7.74M	-9.6%
Q2 FY2024	Jun 30, 2024	$10.04M	-3.9%
Q1 FY2024	Mar 31, 2024	$10.24M	-11.8%
Q4 FY2023	Dec 31, 2023	$11.77M	-10.4%
Q3 FY2023	Sep 30, 2023	$8.57M	-44.9%
Q2 FY2023	Jun 30, 2023	$10.45M	-45.3%
Q1 FY2023	Mar 31, 2023	$11.61M	-48.0%
Q4 FY2022	Dec 31, 2022	$13.13M	-49.5%
Q3 FY2022	Sep 30, 2022	$15.54M	-46.3%
Q2 FY2022	Jun 30, 2022	$19.09M	+96.3%
Q1 FY2022	Mar 31, 2022	$22.31M	+94.7%
Q4 FY2021	Dec 31, 2021	$25.99M	+55.6%
Q2 FY2021	Jun 30, 2021	$28.94M	+116.9%
Q4 FY2020	Dec 31, 2020	$9.72M	-26.8%
Q2 FY2020	Jun 30, 2020	$11.46M	–
Q4 FY2019	Dec 31, 2019	$16.70M	–
Q4 FY2018	Dec 31, 2018	$13.34M	–
Q4 FY2017	Dec 31, 2017	$13.28M	–